Akebia stock tumbles after FDA meeting on vadadustat trial design By Investing.com
Update: 2025-10-29
Description
Akebia Therapeutics' stock plummeted after the company decided not to pursue broad label approval for its anemia drug, Vafseo, due to disagreements with the FDA over a proposed clinical trial. The drug is currently only approved for dialysis patients, and Akebia will now focus on making it the go-to treatment for this group. The company is considering smaller, more specific trials for other patient subgroups, but investors are concerned about the company's future market expansion plans.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
